
STAR.BO Earnings Date: Oct 30, 2026 — Strides Pharma Science Limited
BSE
Updated
When is STAR.BO's next earnings date?
Strides Pharma Science Limited (STAR.BO) is scheduled to report earnings on Friday, October 30, 2026. The consensus estimate is revenue of $14.15B.
How did STAR.BO do in its last earnings report?
In its most recent report on Jul 31, 2026, Strides Pharma Science Limited posted EPS of $17.00. Revenue was $12.65B against a $13.32B estimate.
About Strides Pharma Science Limited
Established in 1990 and based in Bengaluru, India, Strides Pharma Science Limited operates as an international pharmaceutical company, involved in the creation, production, and sale of a wide array of pharmaceutical products. Its operations span numerous global markets, including Africa, Australia, North America, Europe, Asia, and India, and are structured into two main divisions: Pharmaceutical and Biopharmaceutical. The company's portfolio encompasses a comprehensive selection of generic pharmaceuticals, offered in various dosage forms such as tablets, hard and soft gelatin capsules, sachets, liquids, nasal sprays, powders, solids, ointments, and creams. Additionally, Strides Pharma Science develops and markets branded generic products targeting chronic conditions across therapeutic areas like women's health, central nervous system disorders, cardiovascular diseases, diabetes, dermatology, and probiotics, under recognized brands including Renerve, Unibrol, Combiart, Duotab, and Vitafer. Its institutional business also provides essential medications for infectious diseases, such as anti-retrovirals, anti-malarials, anti-tuberculosis drugs, and Hepatitis treatments. A key collaboration with Orbicular Pharmaceutical Technologies Private Limited focuses on the joint development, manufacturing, and commercialization of nasal spray formulations. The company adopted its current name, Strides Pharma Science Limited, in July 2018, having previously been known as Strides Shasun Limited.
🤖 AI Earnings Analysis
STAR.BO trades at 15.5× earnings with an 11.45% profit margin; market cap is about ₹101.2 billion. No news or guidance data provided.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-31 | — | 17.00 | — | $12.65B | — | — | — | — |
Showing last 1 quarters.